Business
Update on Licensing Agreement with BeyondAir Inc.
Update on Licensing Agreement with BeyondAir Inc..
About this update from Niox Group Plc
[{"type":"text","content":"\n \nRNS Number : 4542X Circassia Pharmaceuticals Plc 19 December 2019 \n\nUpdate on Circassia's Licensing Agreement with BeyondAir Inc. for LungFit PH \n \nOxford, UK - 19 December 2019: Circassia Pharmaceuticals plc (\"Circassia\" or \"the Company\"; LSE: CIR), a specialty biopharmaceutical company focused on respiratory disease, provides an update on its licensing agreement with BeyondAir Inc. (previously AIT Therapeutics Inc.) for the commercial rights to the late-stage ventilator-compatible nitric oxide product LungFit PH (previously AirNOvent) in the USA and China. \n \nCircassia has received a notice from BeyondAir stating that it has terminated the agreement for material breach. Circassia refutes the allegations in the strongest terms and believes there are no grounds to terminate the agreement. The Company will enforce its rights under the agreement and defend its position vigorously. \n \nContacts\nCircassia\nIan Johnson, Executive Chairman Tel: +44 (0) 1865 405 560\nJulien Cotta, Chief Financial Officer\nRob Budge, Corporate Communications\n \nPeel Hunt (Nominated Adviser and Joint Broker)\nJames Steel / Dr Christopher Golden Tel: +44 (0) 20 7418 8900\n \nfinnCap (Joint Broker)\nGeoff Nash / Alice Lane Tel: +44 (0) 20 7220 0500\n \nNumis Securities (Joint Broker)\nJames Black / Freddie Barnfield ...